Logo

People in the News: Matt Winkler, Evan Jones

Jan 09, 2013
Premium

Molecular diagnostic company Asuragen has appointed Rollie Carlson to president and CEO, replacing founder Matt Winkler, who will retain the role of chairman of the board and chief scientific officer.

Carlson was previously the president and chief operating officer of Asuragen. Prior to joining the company in 2006, he held several positions at Abbott Laboratories, including vice president and general manager of the Vysis molecular diagnostic business following its acquisition by Abbott.

Foundation Medicine has appointed Evan Jones to its board of directors. He is managing member of jVen Capital and was previously the co-founder, chairman, and CEO of Digene.

Filed under

Clinical Sequencing
Sequencing
Diagnostics
Asuragen
Foundation Medicine
Breaking News
The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.